Sudan Loganathan
Stock Analyst at Stephens
(4.26)
# 1,425
Out of 4,983 analysts
36
Total ratings
61.8%
Success rate
23.6%
Average return
Main Sectors:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADCT ADC Therapeutics | Rated: Buy | $8 → $5 | $1.06 | +371.70% | 3 | Jun 4, 2026 | |
| PVLA Palvella Therapeutics | Initiated Coverage: Buy | $220 | $154.32 | +42.56% | 1 | May 11, 2026 | |
| IMNM Immunome | Rated: Buy | $33 → $30 | $23.93 | +25.37% | 3 | Mar 4, 2026 | |
| KYMR Kymera Therapeutics | Reiterated: Buy | $110 → $100 | $118.48 | -15.60% | 3 | Mar 2, 2026 | |
| ARVN Arvinas | Reiterated: Buy | $15 → $18 | $8.31 | +116.61% | 4 | Feb 25, 2026 | |
| PYXS Pyxis Oncology | Reiterated: Buy | $13 → $8 | $3.41 | +134.60% | 2 | Nov 24, 2025 | |
| CADL Candel Therapeutics | Initiated Coverage: Buy | $15 | $11.34 | +32.28% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Upgraded: Buy | $4 → $6 | $3.42 | n/a | 2 | Sep 15, 2025 | |
| FTH Faeth Therapeutics | Reiterated: Buy | $5 → $35 | $35.13 | n/a | 2 | Jun 30, 2025 | |
| EXEL Exelixis | Upgraded: Buy | $29 → $60 | $58.49 | n/a | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $30 | $25.50 | n/a | 2 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $8 → $1 | $0.365 | n/a | 2 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $5 | $1.19 | n/a | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $10.78 | n/a | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $38.61 | n/a | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $25 | $3.69 | n/a | 1 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $25 | $16.25 | n/a | 1 | May 13, 2024 |
ADC Therapeutics
Jun 4, 2026
Rated: Buy
Price Target: $8 → $5
Current: $1.06
Upside: +371.70%
Palvella Therapeutics
May 11, 2026
Initiated Coverage: Buy
Price Target: $220
Current: $154.32
Upside: +42.56%
Immunome
Mar 4, 2026
Rated: Buy
Price Target: $33 → $30
Current: $23.93
Upside: +25.37%
Kymera Therapeutics
Mar 2, 2026
Reiterated: Buy
Price Target: $110 → $100
Current: $118.48
Upside: -15.60%
Arvinas
Feb 25, 2026
Reiterated: Buy
Price Target: $15 → $18
Current: $8.31
Upside: +116.61%
Pyxis Oncology
Nov 24, 2025
Reiterated: Buy
Price Target: $13 → $8
Current: $3.41
Upside: +134.60%
Candel Therapeutics
Oct 28, 2025
Initiated Coverage: Buy
Price Target: $15
Current: $11.34
Upside: +32.28%
C4 Therapeutics
Sep 15, 2025
Upgraded: Buy
Price Target: $4 → $6
Current: $3.42
Upside: n/a
Faeth Therapeutics
Jun 30, 2025
Reiterated: Buy
Price Target: $5 → $35
Current: $35.13
Upside: n/a
Exelixis
Jun 24, 2025
Upgraded: Buy
Price Target: $29 → $60
Current: $58.49
Upside: n/a
Apr 9, 2025
Reiterated: Buy
Price Target: $20 → $30
Current: $25.50
Upside: n/a
Mar 24, 2025
Downgraded: Hold
Price Target: $8 → $1
Current: $0.365
Upside: n/a
Nov 19, 2024
Reiterated: Buy
Price Target: $25 → $5
Current: $1.19
Upside: n/a
Nov 18, 2024
Initiated Coverage: Buy
Price Target: $15
Current: $10.78
Upside: n/a
Nov 18, 2024
Initiated Coverage: Buy
Price Target: $51
Current: $38.61
Upside: n/a
Nov 7, 2024
Initiated Coverage: Hold
Price Target: $25
Current: $3.69
Upside: n/a
May 13, 2024
Rated: Buy
Price Target: $25
Current: $16.25
Upside: n/a